OSILODROSTAT PHOSPHATE (Isturisa®)
Clinical Indication
Treatment of endogenous Cushing’s syndrome
Date of classification
August 2020
Do not prescribe
Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.